Peptide Profile
Sermorelin
The original growth hormone booster that works with your body's natural rhythm—it tells your pituitary gland to release more GH instead of replacing it, keeping your hormonal feedback system healthy and balanced.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Compound Profile
Scientific & Efficacy Data
C149H246N44O42S
Molecular Formula
3357.9 g/mol
Molecular Weight
10-20 minutes
Half-Life
High when injected subcutaneously; degraded orally
Bioavailability
86168-78-7
CAS #
16132413
PubChem ID ↗
Developed By · 1982
Multiple researchers
Salk Institute / Serono Laboratories
Primary Benefits
At 1 mg twice daily for 14 days, sermorelin raised GH and IGF-1 in older men to levels no different from young men; 0.5 mg twice daily did not reach significance [1]
Bedtime injections raise night-time GH release [3]. GH secretion is tied to deep sleep [10], but no trial on this page measured better sleep with sermorelin, and a GHRH-analog trial found sleep quality unchanged [2]
Evidence is mixed: a GHRH analog increased lean mass in older men only, with no fat change [2], and 6 weeks of nightly sermorelin did not change muscle or fat [3]
Amino Acid Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2Dosing
How much
do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Weeks 4-6
100-200 mcg
Community-practice dose, not one studied in adults. The adult trials used 0.5–1 mg twice daily [1] or 2 mg nightly [3]; the pediatric label dose was 30 mcg/kg at bedtime [6].
3-6 months
200-300 mcg
Community-practice dose. Twice-daily 1 mg (not 200–300 mcg) is the dose that restored GH and IGF-1 in older men [1].
Timing
Best time to take
Bedtime injection (30-60 minutes before sleep) is ideal because it amplifies your body's natural nighttime GH pulse. [6][10] Some protocols add a morning dose on waking for enhanced effects. [1][3]
With food?
Inject on an empty stomach—avoid eating for 2-3 hours before injection. Food, especially carbohydrates, can blunt the GH response by raising insulin levels. Fasting enhances sermorelin's effectiveness.
If stacking
Sermorelin pairs excellently with Ipamorelin or GHRP-2/6 for synergistic GH release—they work through different pathways. [11] If stacking, inject at the same time but at different sites. CJC-1295 (without DAC) can extend the GH pulse duration.
Adjusting Your Dose
Increase if
- +You've used the starting dose for 4+ weeks with no noticeable effects
- +Your IGF-1 levels haven't risen on follow-up blood work
- +You want to try twice-daily dosing for enhanced results
- +Your healthcare provider recommends based on your labs
Decrease if
- -You experience persistent headaches or dizziness
- -Facial flushing becomes uncomfortable or prolonged
- -You feel jittery, anxious, or have trouble sleeping
- -Injection site reactions are significant
Signs of right dose
- ✓Improved sleep quality—falling asleep easier, deeper sleep
- ✓Increased energy and sense of well-being
- ✓Gradual improvements in body composition over months
- ✓IGF-1 levels rising into healthy range on blood work
Suitability
Is this
right for me?
Best For
Adults Experiencing Age-Related GH Decline
After age 30, your growth hormone production naturally declines about 14% per decade. [9] Sermorelin helps restore more youthful GH levels by stimulating your own pituitary rather than shutting it down with external hormones. [1][13] It's like giving your hormone system a gentle nudge back to where it used to be.
Body Composition Optimizers
Evidence for body composition is limited. A GHRH analog increased lean mass in older men but not women, with no change in fat [2]; 6 weeks of nightly sermorelin changed neither muscle nor fat [3]. Larger, longer studies are lacking. [8]
Sleep Quality Seekers
Growth hormone is intimately tied to deep, restorative sleep. [10] By enhancing your natural nighttime GH pulses, sermorelin often improves sleep quality as a welcome side effect. [8] Many users report falling asleep faster and waking more refreshed.
Those Wanting a Safer Alternative to HGH
Direct HGH injections bypass your body's feedback system and can suppress your own production. [13] Sermorelin works differently—it asks your pituitary to make more GH naturally. This preserves your body's regulatory mechanisms and carries a lower risk of side effects. [8]
Consider Alternatives If
Goal: Growth hormone optimization
Consider: Ipamorelin, CJC-1295, Tesamorelin, MK-677 (Ibutamoren)
Goal: Anti-aging and vitality
Consider: Epithalon, GHK-Cu, NAD+ precursors, BPC-157
Goal: Body composition improvement
Consider: Tesamorelin, AOD-9604, Fragment 176-191
Who Should Avoid
Do not use if
- ×You have active cancer or a history of cancer—GH can potentially stimulate tumor growth
- ×You are pregnant or planning to become pregnant—effects on fetal development unknown
- ×You are breastfeeding—the peptide may pass into breast milk
- ×You have a known pituitary tumor or other pituitary disorder
- ×You've had a severe allergic reaction to any peptide or GHRH analog
- ×You have diabetic retinopathy—GH can worsen this condition
Use with caution if
- !You have diabetes—monitor blood sugar closely as GH affects glucose metabolism
- !You have a history of carpal tunnel syndrome—GH can cause fluid retention
- !You're taking glucocorticoids or steroids—these can reduce sermorelin's effectiveness
- !You have hypothyroidism—may need thyroid function monitoring
- !You have sleep apnea—GH therapy has been associated with worsening in some cases
- !You're over 65—start with lower doses and monitor carefully
Administration
How do I
use it?
Reconstitution
What you need
- •Bacteriostatic water (BAC water)—the preservative allows multiple uses
- •Insulin syringes (29-31 gauge) for injection
- •Alcohol swabs for cleaning vial tops and injection sites
- •Your sermorelin powder vial
Injection
Route
Subcutaneous injection (just under the skin)—the standard and most effective method for sermorelin
Best sites
- •Belly fat area (about 2 inches from your belly button)
- •Front or outer thigh (middle section)
- •Back of the upper arm
Technique
- 1.Wash your hands thoroughly with soap and water
- 2.Clean the injection site with an alcohol swab and let it air dry
- 3.Pinch about an inch of skin to create a fold
- 4.Insert the needle at a 45-90 degree angle (45 if lean, 90 if more tissue)
- 5.Inject slowly and steadily over a few seconds
- 6.Wait 5-10 seconds before withdrawing the needle
- 7.Apply light pressure if needed—don't rub the site
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Sermorelin works through the body's own GH feedback, which limits excessive hormone levels. [8][13] On the GEREF label, the most common reaction to repeated injections was a local reaction (about 1 in 6 patients); headache, flushing, dizziness, hyperactivity and somnolence each occurred in under 1%, and many patients developed anti-GRF antibodies. [16] Facial flushing and injection-site pain were the most commonly reported events in the pediatric studies. [6] GEREF was FDA-approved in 1997 for children with GH deficiency. [7]
Safety data come from the GEREF pediatric program and small adult trials of sermorelin itself (0.5–1 mg twice daily for 14 days; 2 mg nightly for 6 weeks), which reported no significant adverse effects. [1][3][6] EMD Serono discontinued GEREF in 2008 and FDA withdrew the approvals at the company's request in 2009, finding this was not for safety or effectiveness reasons. [7] Sermorelin sold today is compounded. [13]
Common Side Effects
Experienced by some users
Injection site reactions
Redness, swelling, itching, or mild pain at the injection site. [6] This is your skin's normal response to the needle and solution.
Management: Rotate injection sites regularly. Use proper technique and let alcohol dry completely before injecting. Usually resolves within 24-48 hours.
Facial flushing
A warm, red feeling in your face shortly after injection. [6][11] This happens because sermorelin can briefly affect blood vessel dilation.
Management: This is temporary and typically lasts only 5-15 minutes. It's not dangerous and usually decreases with continued use as your body adjusts.
Less Common
- •Headache
- •Sleepiness or drowsiness
- •Nausea
- •Hyperactivity or difficulty sleeping
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Any signs of allergic reaction—stop immediately and seek medical help
- ×Persistent headaches that worsen or don't improve after 2 weeks
- ×Significant fluid retention or swelling that doesn't resolve
- ×Development or worsening of carpal tunnel symptoms
- ×Blood sugar control becomes difficult (if diabetic)
- ×Your healthcare provider advises discontinuation based on labs or symptoms
Sermorelin should be used under the guidance of a qualified healthcare provider. While it has a strong safety record, it's a prescription peptide that requires proper monitoring. This information is educational—not medical advice. Always consult your doctor before starting, stopping, or changing any hormone therapy.
Interactions
With other peptides
- ✓Ipamorelin - Excellent synergy—works through GHRP pathway while sermorelin works through GHRH pathway. Together they create stronger, more consistent GH release.
- ✓CJC-1295 (no DAC) - Can extend the duration of the GH pulse initiated by sermorelin. Popular combination in anti-aging protocols.
- ✓GHRP-2 / GHRP-6 - Similar synergy to Ipamorelin. GHRP-6 may increase hunger more. Both enhance sermorelin's effects through complementary pathways.
- ✓BPC-157 - Safe to combine. BPC-157 works on healing while sermorelin supports GH. Different mechanisms, potentially complementary benefits.
With medications
- !Glucocorticoids (prednisone, cortisol) - High-dose steroids can significantly blunt GH response to sermorelin. May reduce effectiveness of therapy.
- !Insulin - GH affects blood sugar. If diabetic, monitor closely and work with your doctor to adjust insulin as needed.
- ✓Thyroid medications - GH can affect thyroid hormone metabolism. Monitor thyroid function regularly and adjust medications if needed.
- !Somatostatin analogs (octreotide) - Directly opposes sermorelin's action by blocking GH release. Do not combine—they work against each other.
With supplements
- ✓Arginine - May enhance GH release when taken with sermorelin. Some practitioners recommend arginine supplementation.
- ✓GABA - May have additive effects on GH release and sleep quality. Generally safe to combine.
- ✓Melatonin - Safe to combine. Both support sleep, and melatonin may have mild GH-supporting effects.
- ✓High-glycemic carbohydrates - Eating carbs around injection time spikes insulin and blunts GH release. Avoid food 2-3 hours before injection.
Effectiveness
Does it
work?
Evidence Level
Moderate human trials
What to Expect
Weeks 1-2
What you might notice
- •Improved sleep quality—falling asleep easier, deeper sleep
- •Mild injection site reactions as your body adjusts
- •Possible facial flushing after injections
- •Subtle increase in energy levels
What's normal
- •Minor injection site redness or swelling
- •Temporary warmth or flushing in face
- •Feeling a bit tired after evening injections
- •Not seeing dramatic changes yet—this is normal
What's next
- →Continue consistent daily injections
- →Track your sleep quality and energy levels
- →Side effects typically diminish as you adjust
Weeks 3-6
What you might notice
- •More consistent improvements in sleep quality
- •Increased energy and sense of well-being
- •Possible subtle improvements in skin quality
- •Better recovery from workouts
What's normal
- •Side effects should be minimal by now
- •Gradual rather than dramatic changes
- •Some variation day-to-day is normal
- •May not see body composition changes yet
What's next
- →Consider blood work to check IGF-1 levels
- →Maintain consistent timing and dosing
- →Real body composition changes take longer
Weeks 6-12
What you might notice
- •More noticeable improvements in body composition
- •Increased lean muscle, especially if exercising
- •Reduction in stubborn body fat
- •Improved skin elasticity and appearance
- •Sustained energy and vitality improvements
What's normal
- •Changes are gradual—don't expect dramatic transformation
- •Benefits compound over time with consistent use
- •Some people respond faster than others
- •Blood work should show rising IGF-1 levels
What's next
- →Most protocols continue for 3-6 months minimum
- →Discuss with your provider about long-term plans
- →Consider periodic blood work monitoring
Months 3-6 and beyond
What you might notice
- •Cumulative benefits become more apparent
- •Significant improvements in body composition
- •Sustained energy, sleep, and recovery benefits
- •Anti-aging effects become noticeable to others
What's normal
- •Benefits plateau at optimal levels
- •Consistent rather than increasing improvements
- •Your body has reached a new baseline
What's next
- →Some people use sermorelin long-term (years)
- →Others cycle on and off (3-6 months on, 1-3 months off)
- →Work with your provider to determine your best approach
Signs It's Working
Sleep and Recovery
- ✓Falling asleep more easily at night
- ✓Deeper, more restorative sleep
- ✓Waking up feeling refreshed rather than groggy
- ✓Faster recovery from workouts and physical activity
- ✓Reduced muscle soreness after exercise
Energy and Well-Being
- ✓Increased daily energy levels
- ✓Improved mental clarity and focus
- ✓Greater sense of overall vitality
- ✓More motivation for exercise and activities
- ✓Improved mood stability
Body Composition (measured over months)
- ✓Gradual increase in lean muscle mass
- ✓Reduction in body fat, especially abdominal
- ✓Clothes fitting differently—looser waist, tighter arms
- ✓Improved muscle definition with exercise
Lab Markers
- ✓IGF-1 levels rising into optimal range
- ✓Improved GH stimulation test results
- ✓Stable or improved metabolic markers
Not Seeing Results?
Common reasons
- •Not injecting on an empty stomach—food and insulin blunt GH release significantly
- •Inconsistent dosing—skipping days reduces effectiveness; daily use is essential
- •Poor timing—daytime injection without fasting is less effective than bedtime dosing
- •Degraded peptide—improper storage or using reconstituted peptide past its shelf life
- •Unrealistic timeline expectations—meaningful body composition changes take 3-6 months
- •Underlying pituitary issues—if your pituitary can't respond, sermorelin won't work (rare)
Key Research
[1]"Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men"
Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR, 1992
Finding: This landmark study showed that twice-daily GHRH (sermorelin) injections in older men completely restored their GH and IGF-1 levels to match those of young men. After just 14 days, the age-related hormone decline was reversed, suggesting that the pituitary gland can still respond—it just needs the right signal.
View Study[2]"Endocrine and metabolic effects of long-term administration of GHRH-(1-29)-NH2 in age-advanced men and women"
Khorram O, Laughlin GA, Yen SS, 1997
Finding: Tested [Nle27]GHRH-(1-29)-NH2, a norleucine analog, not sermorelin itself: 10 mcg/kg nightly for 16 weeks in 9 men and 10 women aged 55-71. GH, IGF-1 and skin thickness rose in both sexes; lean mass, insulin sensitivity, well-being and libido improved in men only; fat, bone density and sleep quality did not change. The only adverse effect was transient hyperlipidemia.
View Study[3]"Effects of single nightly injections of GHRH (1-29) in healthy elderly men"
Vittone J, Blackman MR, Busby-Whitehead J, et al., 1997
Finding: Six weeks of nightly sermorelin increased nocturnal GH release and improved some measures of muscle strength in healthy elderly men. The study suggested that once-daily dosing helps, but twice-daily dosing may be more effective for maximizing benefits.
View Study[4]"In vivo semiquantification of hypothalamic GHRH output in humans: evidence for relative GHRH deficiency in aging"
Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL, 1999
Finding: This study proved that aging causes reduced GHRH output from the hypothalamus—not just a tired pituitary. The pituitary still responds well to GHRH stimulation in elderly people, which is why sermorelin works: it provides the signal the aging hypothalamus no longer sends strongly enough.
View Study[5]"Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels"
Sigalos JT, Pastuszak AW, Allison A, Khera M, 2017
Finding: Men taking sermorelin combined with GHRPs three times daily showed significant increases in IGF-1 levels (from 160 to 239 ng/mL on average). The study confirmed that growth hormone secretagogues are effective for raising IGF-1 in adults seeking to improve body composition.
View Study[6]"Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency"
Prakash A, Goa KL, 1999
Finding: Sermorelin is the shortest synthetic fragment of growth hormone-releasing hormone that retains full biological activity. A single intravenous 1 mcg/kg dose is a rapid, relatively specific provocative test for growth hormone deficiency, and once-daily subcutaneous 30 mcg/kg at bedtime raised height velocity over 12 months in some prepubertal children with idiopathic deficiency. Intravenous single doses and repeated once-daily subcutaneous doses were well tolerated; transient facial flushing and pain at the injection site were the most commonly reported adverse events.
View Study[7]"Determination That GEREF (Sermorelin Acetate) Injection, 0.5 mg Base/Vial and 1.0 mg Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 mg Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
US Food and Drug Administration, 2013
Finding: FDA's regulatory record for sermorelin. GEREF injection 0.5 and 1.0 mg base/vial is NDA 20-443, held by EMD Serono and initially approved on September 26, 1997, indicated for the treatment of idiopathic growth hormone deficiency in children with growth failure; GEREF injection 0.05 mg base/amp is NDA 19-863, initially approved December 28, 1990, indicated for evaluating the ability of the pituitary somatotroph to secrete growth hormone. EMD Serono notified FDA in letters dated July 11 and December 2, 2008 that the products were being discontinued and requested withdrawal of the applications; approval of both NDAs was withdrawn effective June 18, 2009. FDA determined that neither product was withdrawn from sale for reasons of safety or effectiveness.
View Study[8]"The Safety and Efficacy of Growth Hormone Secretagogues"
Sigalos JT, Pastuszak AW, 2018
Finding: Review of clinical studies of growth hormone secretagogues in humans. Secretagogues promote pulsatile release of GH that remains subject to negative feedback and can prevent supra-therapeutic GH levels and their sequelae, in contrast to exogenous GH whose drawbacks are believed to be due in part to impaired regulatory feedback. Across the available studies secretagogues improved growth velocity in children, stimulated appetite, improved lean mass in wasting states and in obese individuals, increased fat-free mass and improved sleep, and were well tolerated, with some concern for increases in blood glucose from decreased insulin sensitivity. The authors note that few long-term, rigorously controlled studies exist.
View Study[9]"Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men"
Iranmanesh A, Lizarralde G, Veldhuis JD, 1991
Finding: Twenty-one healthy men aged 21-71 of near-normal body weight were sampled every 10 minutes for 24 hours and analysed by deconvolution. At a normal body mass index, each decade of increasing age attenuated the GH production rate by 14% and the GH half-life by 6%; age and body mass index together accounted for more than 60% of the variability in 24-hour GH production rates.
View Study[10]"Interrelations between sleep and the somatotropic axis"
Van Cauter E, Plat L, Copinschi G, 1998
Finding: In normal young adults a major GH secretory episode occurs shortly after sleep onset, in temporal association with the first period of slow-wave sleep; in men approximately 70% of daily GH output occurs during early sleep. The sleep-onset GH pulse is caused by a surge of hypothalamic GHRH release coinciding with a circadian period of relative somatostatin disinhibition, and there is a linear relationship between the amount of slow-wave sleep and the amount of concomitant GH secretion. GHRH itself promotes NREM and slow-wave sleep through central mechanisms. During ageing, slow-wave sleep and GH secretion decline with the same chronology.
View Study[11]"Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone"
Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO, 1990
Finding: Eighteen normal men received GH-releasing peptide (GHRP-6) alone and combined with GHRH. Submaximal GHRP doses plus 1 mcg/kg GHRH stimulated GH release synergistically, which the authors take as evidence that GHRP and GHRH act independently through separate mechanisms. Mild facial flushing lasting 1 to 3 minutes occurred in 16 of the 18 subjects who received GHRH.
View Study[12]"Acute hyperglycemia and activation of the beta-adrenergic system exhibit synergistic inhibitory actions on growth hormone (GH) releasing hormone-induced GH release"
Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Park S, 2003
Finding: In healthy subjects given a 100 g oral glucose load 30 minutes before an intravenous GHRH bolus, pretreatment with glucose significantly suppressed GHRH-induced GH secretion. Acute hyperglycaemia stimulates hypothalamic somatostatin release, which in turn suppresses GH secretion from the anterior pituitary; the suppression was independent of beta-adrenergic tone.
View Study[13]"Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?"
Walker RF, 2006
Finding: Editorial contrasting sermorelin with recombinant human GH in age-management practice. Because rhGH is given as a subcutaneous bolus, the amount entering the circulation is not controlled by normal feedback mechanisms, so tissue exposure to elevated concentrations is persistent and may eventually lead to tachyphylaxis and reduced efficacy. Sermorelin instead stimulates the patient's own pituitary by binding specific receptors to increase production and secretion of endogenous GH. The molecule was marketed for years for children with growth retardation but could not compete with rhGH and was withdrawn as a therapeutic entity by the manufacturer; off-label prescribing of sermorelin is not prohibited by federal law.
View Study[14]"Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors"
Cunha SR, Mayo KE, 2002
Finding: GHRH stimulates GH secretion from somatotroph cells of the anterior pituitary via a pathway in which the GHRH receptor activates adenylyl cyclase and increases cAMP production. GH secretagogues bind a distinct G protein-coupled receptor that activates phospholipase C and raises calcium and diacylglycerol rather than cAMP; co-activation of the two receptors roughly doubled the cAMP response to GHRH alone.
View Study[15]"Familial Growth Hormone Deficiency and Mutations in the GHRH Receptor Gene"
Alba M, Salvatori R, 2004
Finding: GHRH is necessary for the proliferation of the somatotropic cells of the anterior pituitary and for the synthesis and secretion of GH. It is released by the hypothalamus into the portal hypophysial circulation and binds a membrane surface receptor, the GHRH receptor, expressed by the somatotropic cells; inactivating mutations of that receptor are a relatively common cause of inherited isolated GH deficiency.
View Study[16]"GEREF (sermorelin acetate) — Adverse Reactions, US prescribing information (FDA revision 10/2/2001), reproduced by RxList"
Serono Laboratories / RxList (WebMD), 2001
Finding: Repeated subcutaneous treatment: the most common treatment-related adverse event, in about 1 patient in 6, is a local injection reaction of pain, swelling or redness. Other treatment-related events occurred individually at under 1% — headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria. Intravenous diagnostic use: flushing of the face, injection site pain, redness and/or swelling, nausea, headache, vomiting, dysgeusia, pallor and tightness in the chest. A large proportion of patients develop anti-GRF antibodies at least once during treatment. GEREF was discontinued in the US in 2008 and FDA no longer hosts the label for either NDA 19-863 or NDA 20-443; this is a publisher's reproduction of it, not an FDA-hosted document.
View StudySimple explanation
As you age, your brain's hypothalamus produces less of a hormone called GHRH (growth hormone-releasing hormone). [4] This is the signal that tells your pituitary gland to release growth hormone. Less signal means less GH, which leads to increased body fat, reduced muscle, lower energy, and poorer sleep. Sermorelin is a synthetic version of the first 29 amino acids of natural GHRH—the active part that sends the 'release GH' message. [6] When you inject sermorelin, it's like giving your pituitary the signal it's been missing. Your pituitary then releases GH naturally, just like it did when you were younger. The beauty is that your body's feedback system stays intact, so you can't easily overdose or shut down your natural production. [8][13]
Detailed mechanism
Sermorelin (GHRH 1-29, also known as GRF 1-29 NH2) is a synthetic analog comprising the first 29 amino acids of the 44-amino acid native human growth hormone-releasing hormone. This N-terminal fragment retains full biological activity. [6] Upon subcutaneous administration, sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. [15] GHRHR is a G-protein coupled receptor that, when activated, stimulates adenylyl cyclase, increasing intracellular cAMP. [14] This activates protein kinase A, leading to calcium influx and subsequent GH release from secretory vesicles. Sermorelin also stimulates GH gene transcription and somatotroph proliferation with chronic use. [15] The peptide preserves the pulsatile nature of GH secretion and maintains the negative feedback loop via IGF-1 and somatostatin, providing an inherent safety mechanism against supraphysiological GH levels. [8] The short half-life (10-20 minutes) necessitates strategic timing—bedtime administration amplifies the natural nocturnal GH surge, [10] while twice-daily protocols maximize 24-hour integrated GH exposure. Age-related decline in GH is attributed partly to reduced hypothalamic GHRH output [4] and increased somatostatin tone; sermorelin addresses the former directly.
Works well with
- ✓Ipamorelin
- ✓CJC-1295
- ✓GHRP-2
- ✓GHRP-6
- ✓MK-677
Avoid combining with
- ×Direct HGH injections (redundant and may suppress natural production)
- ×High-dose glucocorticoids (can blunt GH response)
- ×Somatostatin or its analogs (directly opposes sermorelin's action)
Frequently Asked Questions